307 related articles for article (PubMed ID: 27162324)
1. Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases.
Yamashita H; Niibe Y; Yamamoto T; Katsui K; Jingu K; Kanazawa S; Terahara A; Nakagawa K
Jpn J Clin Oncol; 2016 Jul; 46(7):687-91. PubMed ID: 27162324
[TBL] [Abstract][Full Text] [Related]
2. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic Body Radiotherapy Results for Pulmonary Oligometastases: A Two-Institution Collaborative Investigation.
Niibe Y; Yamashita H; Sekiguchi K; Takahashi W; Shiraishi K; Okuma K; Terahara A; Kawamori J; Nakagawa K
Anticancer Res; 2015 Sep; 35(9):4903-8. PubMed ID: 26254386
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy: A Nationwide Survey of 1,378 Patients.
Niibe Y; Yamamoto T; Onishi H; Yamashita H; Katsui K; Matsumoto Y; Oh RJ; Aoki M; Shintani T; Yamada K; Kobayashi M; Ozaki M; Manabe Y; Yahara K; Nishikawa A; Kakuhara H; Yamamoto K; Inoue T; Takada YU; Nagata K; Suzuki O; Terahara A; Jingu K
Anticancer Res; 2020 Jan; 40(1):393-399. PubMed ID: 31892592
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
6. Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy.
Sharma A; Duijm M; Oomen-de Hoop E; Aerts JG; Verhoef C; Hoogeman M; Nuyttens JJ
Acta Oncol; 2019 Jan; 58(1):74-80. PubMed ID: 30280633
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study.
Mazzola R; Fersino S; Ferrera G; Targher G; Figlia V; Triggiani L; Pasinetti N; Lo Casto A; Ruggieri R; Magrini SM; Alongi F
Med Oncol; 2018 Aug; 35(9):121. PubMed ID: 30076479
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study.
Aoki M; Hatayama Y; Kawaguchi H; Hirose K; Sato M; Akimoto H; Miura H; Ono S; Takai Y
J Radiat Res; 2016 Jan; 57(1):55-61. PubMed ID: 26494115
[TBL] [Abstract][Full Text] [Related]
10. Analyses of the local control of pulmonary Oligometastases after stereotactic body radiotherapy and the impact of local control on survival.
Yamamoto T; Niibe Y; Aoki M; Shintani T; Yamada K; Kobayashi M; Yamashita H; Ozaki M; Manabe Y; Onishi H; Yahara K; Nishikawa A; Katsui K; Oh RJ; Terahara A; Jingu K
BMC Cancer; 2020 Oct; 20(1):997. PubMed ID: 33054721
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy.
Sharma A; Duijm M; Oomen-de Hoop E; Aerts JG; Verhoef C; Hoogeman M; Nuyttens JJ
Acta Oncol; 2018 Aug; 57(8):1031-1037. PubMed ID: 29488414
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
13. Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence.
Nakamura M; Hashimoto N; Mayahara H; Uezono H; Harada A; Nishikawa R; Matsuo Y; Kawaguchi H; Nishimura H
Radiat Oncol; 2018 Apr; 13(1):75. PubMed ID: 29688858
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions.
Inoue T; Katoh N; Aoyama H; Onimaru R; Taguchi H; Onodera S; Yamaguchi S; Shirato H
Jpn J Clin Oncol; 2010 Aug; 40(8):788-94. PubMed ID: 20406944
[TBL] [Abstract][Full Text] [Related]
15. Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT.
Hörner-Rieber J; Bernhardt D; Blanck O; Duma M; Eich HT; Gerum S; Gkika E; Hass P; Henkenberens C; Herold HU; Hildebrandt G; Imhoff D; Kahl H; Janssen S; Jurianz K; Krempien R; Lautenschläger SF; Lohaus F; Mueller AC; Petersen C; Sackerer I; Scafa D; Schrade E; Uhlmann L; Wittig A; Guckenberger M
Clin Lung Cancer; 2019 Nov; 20(6):e667-e677. PubMed ID: 31327644
[TBL] [Abstract][Full Text] [Related]
16. Analyses of local control and survival after stereotactic body radiotherapy for pulmonary oligometastases from colorectal adenocarcinoma.
Yamamoto T; Niibe Y; Matsumoto Y; Onishi H; Aoki M; Nishikawa A; Oh RJ; Shintani T; Yahara K; Ozaki M; Manabe Y; Jingu K
J Radiat Res; 2020 Nov; 61(6):935-944. PubMed ID: 32940330
[TBL] [Abstract][Full Text] [Related]
17. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases.
Andratschke N; Alheid H; Allgäuer M; Becker G; Blanck O; Boda-Heggemann J; Brunner T; Duma M; Gerum S; Guckenberger M; Hildebrandt G; Klement RJ; Lewitzki V; Ostheimer C; Papachristofilou A; Petersen C; Schneider T; Semrau R; Wachter S; Habermehl D
BMC Cancer; 2018 Mar; 18(1):283. PubMed ID: 29534687
[TBL] [Abstract][Full Text] [Related]
18. Factors related to primary cancer death and non-primary cancer death in patients treated with stereotactic body radiotherapy for pulmonary oligometastases.
Yamamoto T; Niibe Y; Matsumoto Y; Aoki M; Oh RJ; Ozaki M; Kobayashi M; Manabe Y; Shintani T; Dekura Y; Onishi H; Yamashita H; Jingu K
Cancer Med; 2020 Dec; 9(23):8902-8911. PubMed ID: 33022899
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
[TBL] [Abstract][Full Text] [Related]
20. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases.
Fumagalli I; Bibault JE; Dewas S; Kramar A; Mirabel X; Prevost B; Lacornerie T; Jerraya H; Lartigau E
Radiat Oncol; 2012 Sep; 7():164. PubMed ID: 23014094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]